Takashi Yamaguchi1, Noriko Kohyama2, Miki Takenaka2, Takahiro Okada2, Tatsuya Kurihara3, Kosuke Sakurai4, Yusuke Miwa4, Mari Kogo2. 1. Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan. t-yamaguchi@cmed.showa-u.ac.jp. 2. Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan. 3. Division of Natural Medicine and Therapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan. 4. Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Abstract
INTRODUCTION: We investigated factors predicting the addition of disease-modifying antirheumatic drugs (DMARDs) after an initial methotrexate (MTX) monotherapy in rheumatoid arthritis (RA) patients to support an early decision on the DMARDs addition. METHODS: This retrospective cohort study included 311 patients who were diagnosed with RA and started on MTX monotherapy at Showa University Hospital, Japan. The outcome was addition of DMARDs after an initial MTX monotherapy at 6 months. Baseline patient characteristics were compared between the DMARDs addition and MTX monotherapy continuation groups, and significant independent predictive factors for the addition of DMARDs were selected using multivariate analysis. RESULTS: The median age of patients was 62 years (range 24-90), 170 patients (73%) were women, the median swollen 28-joint count (SJC28) was 3 (0-28), and the median tender 28-joint count (TJC28) was 5 (0-28). DMARDs were added in 65 (27.9%) patients. In the univariate analysis, higher TJC28 and SJC28, concomitant use of nonsteroidal anti-inflammatory drugs, and intra-articular glucocorticoid (GC) injection history were significantly associated with the DMARDs addition. In the multivariate analysis, by adding covariates to the variables identified in the univariate analysis, SJC28 (odds ratio [OR] 1.390 per 5 joints increase; 95% confidence interval [CI], 1.036-1.866) and intra-articular GC injection history (OR 3.678; 95% CI, 1.170-11.557) were independent predictors of DMARDs addition. CONCLUSION: A higher SJC28 and intra-articular GC injection history may be useful predictors of DMARDs addition after the initial MTX monotherapy. We expect that using these predictors will enable an earlier shift to a more aggressive treatment. Key Points ・We performed a retrospective cohort study with the addition of DMARDs as the outcome in patients with RA who were started on MTX monotherapy. ・A higher SJC28 (OR 1.390; 95% CI, 1.036-1.866) and an intra-articular GC injection history (OR 3.678; 95% CI, 1.170-11.557) may be useful predictors for the addition of DMARDs of initiating MTX monotherapy at 6 months. ・The use of such indicators may support an early decision on the addition of DMARDs after the initial MTX monotherapy.
INTRODUCTION: We investigated factors predicting the addition of disease-modifying antirheumatic drugs (DMARDs) after an initial methotrexate (MTX) monotherapy in rheumatoid arthritis (RA) patients to support an early decision on the DMARDs addition. METHODS: This retrospective cohort study included 311 patients who were diagnosed with RA and started on MTX monotherapy at Showa University Hospital, Japan. The outcome was addition of DMARDs after an initial MTX monotherapy at 6 months. Baseline patient characteristics were compared between the DMARDs addition and MTX monotherapy continuation groups, and significant independent predictive factors for the addition of DMARDs were selected using multivariate analysis. RESULTS: The median age of patients was 62 years (range 24-90), 170 patients (73%) were women, the median swollen 28-joint count (SJC28) was 3 (0-28), and the median tender 28-joint count (TJC28) was 5 (0-28). DMARDs were added in 65 (27.9%) patients. In the univariate analysis, higher TJC28 and SJC28, concomitant use of nonsteroidal anti-inflammatory drugs, and intra-articular glucocorticoid (GC) injection history were significantly associated with the DMARDs addition. In the multivariate analysis, by adding covariates to the variables identified in the univariate analysis, SJC28 (odds ratio [OR] 1.390 per 5 joints increase; 95% confidence interval [CI], 1.036-1.866) and intra-articular GC injection history (OR 3.678; 95% CI, 1.170-11.557) were independent predictors of DMARDs addition. CONCLUSION: A higher SJC28 and intra-articular GC injection history may be useful predictors of DMARDs addition after the initial MTX monotherapy. We expect that using these predictors will enable an earlier shift to a more aggressive treatment. Key Points ・We performed a retrospective cohort study with the addition of DMARDs as the outcome in patients with RA who were started on MTX monotherapy. ・A higher SJC28 (OR 1.390; 95% CI, 1.036-1.866) and an intra-articular GC injection history (OR 3.678; 95% CI, 1.170-11.557) may be useful predictors for the addition of DMARDs of initiating MTX monotherapy at 6 months. ・The use of such indicators may support an early decision on the addition of DMARDs after the initial MTX monotherapy.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker Journal: Ann Rheum Dis Date: 2010-09 Impact factor: 19.103
Authors: Cynthia S Crowson; Eric L Matteson; Elena Myasoedova; Clement J Michet; Floranne C Ernste; Kenneth J Warrington; John M Davis; Gene G Hunder; Terry M Therneau; Sherine E Gabriel Journal: Arthritis Rheum Date: 2011-03
Authors: Naomi B Klarenbeek; Melek Güler-Yüksel; Sjoerd M van der Kooij; K Huub Han; H Karel Ronday; Pit J S M Kerstens; Patrick E H Seys; Tom W J Huizinga; Ben A C Dijkmans; Cornelia F Allaart Journal: Ann Rheum Dis Date: 2011-03-17 Impact factor: 19.103
Authors: Saedis Saevarsdottir; Helena Wallin; Maria Seddighzadeh; Sofia Ernestam; Pierre Geborek; Ingemar F Petersson; Johan Bratt; Ronald F van Vollenhoven Journal: Ann Rheum Dis Date: 2010-12-13 Impact factor: 19.103
Authors: Josef S Smolen; Robert B M Landewé; Johannes W J Bijlsma; Gerd R Burmester; Maxime Dougados; Andreas Kerschbaumer; Iain B McInnes; Alexandre Sepriano; Ronald F van Vollenhoven; Maarten de Wit; Daniel Aletaha; Martin Aringer; John Askling; Alejandro Balsa; Maarten Boers; Alfons A den Broeder; Maya H Buch; Frank Buttgereit; Roberto Caporali; Mario Humberto Cardiel; Diederik De Cock; Catalin Codreanu; Maurizio Cutolo; Christopher John Edwards; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Laure Gossec; Jacques-Eric Gottenberg; Merete Lund Hetland; Tom W J Huizinga; Marios Koloumas; Zhanguo Li; Xavier Mariette; Ulf Müller-Ladner; Eduardo F Mysler; Jose A P da Silva; Gyula Poór; Janet E Pope; Andrea Rubbert-Roth; Adeline Ruyssen-Witrand; Kenneth G Saag; Anja Strangfeld; Tsutomu Takeuchi; Marieke Voshaar; René Westhovens; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2020-01-22 Impact factor: 19.103
Authors: Johannes W J Bijlsma; Paco M J Welsing; Thasia G Woodworth; Leonie M Middelink; Attila Pethö-Schramm; Corrado Bernasconi; Michelle E A Borm; Cornelis H Wortel; Evert Jan Ter Borg; Z Nazira Jahangier; Willemijn H van der Laan; George A W Bruyn; Paul Baudoin; Siska Wijngaarden; Petra A J M Vos; Reinhard Bos; Mirian J F Starmans; Eduard N Griep; Joanna R M Griep-Wentink; Cornelia F Allaart; Anton H M Heurkens; Xavier M Teitsma; Janneke Tekstra; Anne Carien A Marijnissen; Floris P J Lafeber; Johannes W G Jacobs Journal: Lancet Date: 2016-06-07 Impact factor: 79.321
Authors: Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde Journal: Ann Rheum Dis Date: 2015-05-12 Impact factor: 19.103
Authors: Josef S Smolen; Ronald F van Vollenhoven; Stefan Florentinus; Su Chen; Jessica L Suboticki; Arthur Kavanaugh Journal: Ann Rheum Dis Date: 2018-08-03 Impact factor: 19.103